Article

Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock.

Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, London, United Kingdom.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 12/2010; 182(12):1506-15. DOI: 10.1164/rccm.201002-0240OC
Source: PubMed

ABSTRACT Peroxisome proliferator-activated receptor (PPAR)-β/δ is a transcription factor that belongs to the PPAR nuclear hormone receptor family, but the role of PPAR-β/δ in sepsis is unknown.
We investigated the role of PPAR-β/δ in murine models of LPS-induced organ injury and dysfunction and cecal ligation and puncture (CLP)-induced polymicrobial sepsis.
Wild-type (WT) and PPAR-β/δ knockout (KO) mice and C57BL/6 mice were subjected to LPS for 16 hours. C57BL/6 mice received the PPAR-β/δ agonist GW0742 (0.03 mg/kg intravenously, 1 h after LPS) or GW0742 plus the PPAR-β/δ antagonist GSK0660 (0.1 mg/kg intravenously, 30 min before LPS). CD-1 mice subjected to CLP received GW0742 or GW0742 plus GSK0660.
In PPAR-β/δ KO mice, endotoxemia exacerbated organ injury and dysfunction (cardiac, renal, and hepatic) and inflammation (lung) compared with WT mice. In C57BL/6 mice subjected to endotoxemia, GW0742 significantly (1) attenuated organ (cardiac and renal) dysfunction and inflammation (lung); (2) increased the phosphorylation of Akt and glycogen synthase kinase (GSK)-3β; (3) attenuated the increase in extracellular signal-regulated kinase (ERK)1/2 and signal transducer and activator of transcription (STAT)-3 phosphorylation; and (4) attenuated the activation of nuclear factor (NF)-κB and the expression of inducible nitric oxide synthase (iNOS). In CD-1 mice subjected to CLP, GW0742 improved 10-day survival. All the observed beneficial effects of GW0742 were attenuated by the PPAR-β/δ antagonist GSK0660.
PPAR-β/δ protects against multiple organ injury and dysfunction, and inflammation caused by endotoxic shock and improves survival in polymicrobial sepsis by a mechanism that may involve activation of Akt and inhibition of GSK-3β and NF-κB.

Download full-text

Full-text

Available from: Marcin Osuchowski, Jul 06, 2015
0 Followers
 · 
267 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nuclear factor (NF)-κB plays a pivotal role in sepsis. Activation of NF-κB is initiated by the signal-induced ubiquitination and subsequent degradation of inhibitors of kappa B (IκBs) primarily via activation of the IκB kinase (IKK). This study was designed to investigate the effects of IKK inhibition on sepsis-associated multiple organ dysfunction/injury (MOD) and to elucidate underlying signaling mechanisms in two different in vivo models: Male C57BL/6 mice were subjected to either bacterial cell wall components [lipopolysaccharide (LPS)/peptidoglycan (PepG)] or underwent cecal ligation and puncture (CLP) to induce sepsis-associated MOD. One hour after LPS/PepG or CLP mice were treated with the IKK inhibitor IKK 16 (1 mg/kg). At 24 hours parameters of organ dysfunction/injury were assessed in both models. Mice developed a significant impairment in systolic contractility (echocardiography), a significant increase in serum creatinine, alanine aminotransferase as well as lung myeloperoxidase activity, and, thus, cardiac dysfunction, renal dysfunction and hepatocellular injury as well as lung inflammation, respectively. Treatment with IKK 16 attenuated the impairment in systolic contractility, renal dysfunction, hepatocellular injury and lung inflammation in LPS/PepG induced multiple organ dysfunction/injury and in polymicrobial sepsis. Compared with mice that were injected with LPS/PepG or underwent CLP, immunoblot analyzes of heart and liver tissues from mice that were injected with LPS/PepG or underwent CLP and treated with IKK 16 revealed a significant attenuation of the i) increased phosphorylation of IκBα; ii) increased nuclear translocation of the NF-κB subunit p65; iii) significant increase in inducible nitric oxide synthase (iNOS) expression; and iv) revealed a significant increase in the phosphorylation of Akt and endothelial nitric oxide synthase (eNOS). Here, we report for the first time that delayed IKK inhibition reduces MOD in experimental sepsis. We suggest that this protective effect is (at least in part) attributable to inhibition of inflammation through NF-κB, the subsequent decreased iNOS expression and the activation of the Akt/eNOS survival pathway.
    Disease Models and Mechanisms 05/2013; DOI:10.1242/dmm.012435 · 5.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this Update, we provide an overview of selected studies published in 2010 in the American Journal of Respiratory and Critical Care Medicine and other journals focusing on novel findings on acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS). We attempt to highlight key articles that advanced our understanding on clinical and basic aspects of critical illness.
    American Journal of Respiratory and Critical Care Medicine 05/2011; 183(9):1147-52. DOI:10.1164/rccm.201102-0327UP · 11.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The association between metabolic syndrome and cardiovascular diseases raises important questions about the underlying pathological processes, especially for designing targeted therapeutic interventions. The Peroxisome Proliferators Activated Receptors (PPARs) are ligand-activated transcription factors that control lipid and glucose metabolism. Accumulating data suggest that PPARs may serve as potential targets for treating metabolic diseases and their cardiovascular complications. PPARs regulate gene expression by binding with RXR as a heterodimeric partner to specific DNA sequences, termed PPAR response elements. In addition, PPARs may modulate gene transcription also by directly interfering with other transcription factor pathways in a DNA-binding independent manner. To date, three different PPAR isoforms, designated α, β/δ and γ, have been identified. PPARα and PPARγ are the most extensively examined and characterized, mainly because they are activated by compounds, such as fibrates and thiazolidinediones, that are in clinical use for the treatment of hypertriglyceridemia and insulin resistance, respectively. In contrast the role of PPARβ/δ in metabolism has been less investigated. The recent availability of specific PPARβ/δ agonists revealed that PPARβ/δ plays a crucial role in fatty acid metabolism in several tissues. Besides, PPARβ/δ activation exerts beneficial effects against organ-related ischemic events, such as myocardial and cerebral infarction, which are among the most critical cardiovascular complications evoked by metabolic dysregulation. This paper reviews the evidence and recent developments relating to the potential therapeutic effects of PPARβ/δ agonists in the treatment of metabolic syndrome and its associated cardiovascular risk factors.
    06/2011; 11(4):273-84. DOI:10.2174/187153011797881175